Robin Shane Readnour
Director at AN2 Therapeutics, Inc. (ANTX)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $317K
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Sep 11SEC | ANTXAN2 Therapeutics, Inc. | Sell Plan | 523557,467 held (−0%) | $6.02 | $3K | -26.9% |
| Sep 11SEC | ANTXAN2 Therapeutics, Inc. | Sell Plan | 585624,765 held (−0%) | $6.02 | $4K | -26.9% |
| Sep 8SEC | ANTXAN2 Therapeutics, Inc. | Sell Plan | 2,877562,715 held (−1%) | $6.07 | $17K | -27.5% |
| Sep 8SEC | ANTXAN2 Therapeutics, Inc. | Sell Plan | 3,223630,644 held (−1%) | $6.07 | $20K | -27.5% |
| Sep 8SEC | ANTXAN2 Therapeutics, Inc. | Sell Plan | 4,725557,990 held (−1%) | $6.02 | $28K | -26.9% |
| Sep 8SEC | ANTXAN2 Therapeutics, Inc. | Sell Plan | 5,294625,350 held (−1%) | $6.02 | $32K | -26.9% |
| Aug 19SEC | ANTXAN2 Therapeutics, Inc. | Sell Plan | 16,696565,592 held (−3%) | $6.01 | $100K | -26.8% |
| Aug 19SEC | ANTXAN2 Therapeutics, Inc. | Sell Plan | 18,706633,867 held (−3%) | $6.01 | $112K | -26.8% |
- Sell
Director Robin Shane Readnour sold $3K of ANTX at $6.02 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Robin Shane Readnour sold $4K of ANTX at $6.02 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Robin Shane Readnour sold $17K of ANTX at $6.07 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Robin Shane Readnour sold $20K of ANTX at $6.07 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Robin Shane Readnour sold $28K of ANTX at $6.02 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Robin Shane Readnour sold $32K of ANTX at $6.02 — pre-scheduled 10b5-1 plan sale.